- Home
- LPX vs LEGN Comparison
LPX vs LEGN Comparison
Compare LPX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPX | LEGN |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPX | LEGN |
|---|---|---|
| Price | $70.81 | N/A |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | |
| Target Price | $110.17 | N/A |
| AVG Volume (30 Days) | 671.5K | N/A |
| Earning Date | 05-05-2026 | 04-05-2026 |
| Dividend Yield | 1.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 2.08 | N/A |
| Revenue | $2,708,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.66 | N/A |
| P/E Ratio | $34.06 | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.63 | N/A |
| 52 Week High | $102.86 | N/A |
Technical Indicators
Market Signals| Indicator | LPX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 56.74 |
| Support Level | $69.63 | $17.46 |
| Resistance Level | $75.69 | $20.39 |
| Average True Range (ATR) | 2.65 | 0.70 |
| MACD | 0.20 | 0.15 |
| Stochastic Oscillator | 14.34 | 91.73 |
Price Performance
Historical ComparisonAbout LPX Louisiana-Pacific Corporation
Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.